Advaxis ROA 2024

Advaxis làm gì?

Advaxis Inc is a biopharmaceutical company based in Princeton, New Jersey. It was founded in 2002 by Dr. John Rothman and Dr. Yvonne Paterson, who are experts in the field of immuno-oncology. Advaxis's mission is to develop a new generation of immunotherapies based on the use of Listeria-based vaccines. These vaccines are capable of activating the body's immune system and targeting cancer cells specifically. Advaxis's business model is based on licensing its technology platform to other pharmaceutical companies and generating income in this way. In addition, Advaxis develops and distributes its own products based on the technology platform. Advaxis currently focuses on three different areas: 1. Immuno-oncology Immuno-oncology encompasses all treatments in which the body's immune system is used to combat cancer cells. Advaxis aims to develop a new generation of cancer therapies based on the use of Listeria-based vaccines. The company has already achieved promising results in clinical trials in the fight against various types of cancer, including cervical cancer, prostate cancer, and lung cancer. 2. Infectious diseases Infectious diseases refer to diseases caused by pathogens such as viruses, bacteria, or fungi. Advaxis has developed a technology platform that is suitable for the treatment of infectious diseases. The platform is based on the use of Listeria-based vaccines that specifically target infectious pathogens. 3. Personalized medicine Personalized medicine refers to the customization of medical treatments to individual patient needs and characteristics. Advaxis has developed a technology platform that is suitable for the production of personalized cancer vaccines. The platform is based on the use of Listeria-based vaccines tailored to the individual needs of the patient. Advaxis currently offers several products based on the technology platform. These include: 1. AXAL AXAL is a vaccine developed for the treatment of cervical cancer. In clinical trials, the vaccine has shown promising results and has been awarded "Breakthrough Therapy" status by the US Food and Drug Administration (FDA). 2. ADXS-PSA ADXS-PSA is a vaccine developed for the treatment of prostate cancer. In clinical trials, the vaccine has shown promising results and is currently being further developed. 3. ADXS-HOT ADXS-HOT is a personalized cancer vaccine tailored to the individual needs of the patient. The vaccine is based on the use of Listeria-based vaccines and has been developed for the treatment of various types of cancer, including lung cancer and colorectal cancer. Advaxis is an innovative biopharmaceutical company focused on the development of new immunotherapies. The company has already achieved promising results in clinical trials and aims to develop a new generation of cancer therapies that have the potential to improve the lives of millions of people worldwide. Advaxis ist eines der beliebtesten Unternehmen auf Eulerpool.com.